| Literature DB >> 29700266 |
Cameron Myhrvold1,2, Catherine A Freije1,2,3, Jonathan S Gootenberg4,5,6,7,8, Omar O Abudayyeh4,6,7,8,9, Hayden C Metsky4,10, Ann F Durbin3,11, Max J Kellner4, Amanda L Tan12, Lauren M Paul12, Leda A Parham13, Kimberly F Garcia13, Kayla G Barnes4,2,14, Bridget Chak4,2, Adriano Mondini15, Mauricio L Nogueira16, Sharon Isern12, Scott F Michael12, Ivette Lorenzana13, Nathan L Yozwiak4,2, Bronwyn L MacInnis4,14, Irene Bosch11,17, Lee Gehrke3,11,18, Feng Zhang4,6,7,8, Pardis C Sabeti1,2,3,14,19.
Abstract
Mitigating global infectious disease requires diagnostic tools that are sensitive, specific, and rapidly field deployable. In this study, we demonstrate that the Cas13-based SHERLOCK (specific high-sensitivity enzymatic reporter unlocking) platform can detect Zika virus (ZIKV) and dengue virus (DENV) in patient samples at concentrations as low as 1 copy per microliter. We developed HUDSON (heating unextracted diagnostic samples to obliterate nucleases), a protocol that pairs with SHERLOCK for viral detection directly from bodily fluids, enabling instrument-free DENV detection directly from patient samples in <2 hours. We further demonstrate that SHERLOCK can distinguish the four DENV serotypes, as well as region-specific strains of ZIKV from the 2015-2016 pandemic. Finally, we report the rapid (<1 week) design and testing of instrument-free assays to detect clinically relevant viral single-nucleotide polymorphisms.Entities:
Mesh：
Substances：
Year: 2018 PMID： 29700266 PMCID： PMC6197056 DOI： 10.1126/science.aas8836
Source DB: PubMed Journal: Science ISSN： 0036-8075 Impact factor: 47.728